We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure coreplatform@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Oral rotavirus vaccine efficacy estimates from randomised controlled trials are highly variable across settings. Although the randomised study design increases the likelihood of internal validity of findings, results from trials may not always apply outside the context of the study due to differences between trial participants and the target population. Here, we used a weight-based method to transport results from a monovalent rotavirus vaccine clinical trial conducted in Malawi between 2005 and 2008 to a target population of all trial-eligible children in Malawi, represented by data from the 2015–2016 Malawi Demographic and Health Survey (DHS). We reweighted trial participants to reflect the population characteristics described by the Malawi DHS. Vaccine efficacy was estimated for 1008 trial participants after applying these weights such that they represented trial-eligible children in Malawi. We also conducted subgroup analyses to examine the heterogeneous treatment effects by stunting and tuberculosis vaccination status at enrolment. In the original trial, the estimates of one-year vaccine efficacy against severe rotavirus gastroenteritis and any-severity rotavirus gastroenteritis in Malawi were 49.2% (95% CI 15.6%–70.3%) and 32.1% (95% CI 2.5%–53.1%), respectively. After weighting trial participants to represent all trial-eligible children in Malawi, vaccine efficacy increased to 62.2% (95% CI 35.5%–79.0%) against severe rotavirus gastroenteritis and 38.9% (95% CI 11.4%–58.5%) against any-severity rotavirus gastroenteritis. Rotavirus vaccine efficacy may differ between trial participants and target populations when these two populations differ. Differences in tuberculosis vaccination status between the trial sample and DHS population contributed to varying trial and target population vaccine efficacy estimates.
DSM-V describes three eating disorders (anorexia nervosa, bulimia nervosa, and binge eating disorder), three feeding disorders (avoidant/restrictive food intake disorder, pica, and rumination disorder), and two residual feeding and eating disorder categories (APA, 2013). Although these disorders contain some overlapping features, an individual can receive just one feeding or eating disorder diagnosis at a time. The only exception is pica, which can be diagnosed concurrently with another feeding or eating disorder if the pica behavior is severe enough to warrant additional clinical attention.
This chapter describes the primary interventions for the lack of interest presentation of ARFID, including:
Step-by-step instructions for interoceptive exposures to habituate to feelings of nausea, fullness, or bloating to support eating enough for adequate nutritional intake
Self-monitoring to increase awareness of hunger cues
Reconnecting to the pleasure of eating by using the five steps with highly preferred foods
This chapter provides a basic introduction to the relationship between thoughts, feelings, and behaviors, and introduces our cognitive-behavioral model of ARFID. We return to the case examples from Chapter 1 to illustrate a cognitive-behavioral understanding of sensory sensitivity, fear of aversive consequences, and lack of interest in eating or food.
This chapter explains what avoidant/restrictive food intake disorder (ARFID) is and provides diverse and relatable case examples of each of the three prototypical ARFID presentations, including sensory sensitivity, fear of aversive consequences, and lack of interest in eating or food.
This chapter describes the evidence for cognitive-behavioral therapy for ARFID and highlights exciting future directions in ARFID treatment and research.
This chapter will help the reader assess the adequacy of his of her current diet and determine which module(s) (described in chapters 6, 7, and 8) is/are most appropriate to complete as next steps. Key components of this chapter will include:
Information about common nutrition deficiencies observed in ARFID
The five basic food groups (from US MyPlate schematic) and the importance of eating a varied diet
Strategically selecting fruits, vegetables, proteins, dairy, and grains to learn about that will support resolution of nutrition deficiencies, encourage further weight gain (if needed), and/or reduce psychosocial impairment
Selecting whether to tackle sensory sensitivity, fear of aversive consequences, and/or lack of interest in eating or food, and in what order